Analyst firms · Wolfe Research · MRNA

Wolfe Research MRNA price target and rating history

Moderna Inc. (MRNA) · Health Care

Wolfe Research rates Moderna Inc. (MRNA) Peer Perform with a $40 price target, as of its latest action on Aug 25, 2026. It has published 3 rating actions on MRNA since November 2021, including 1 upgrade and 0 downgrades. Across 6 firms with a MRNA price target in the last 12 months, the median target is $57.

Current rating

Peer Perform

Price target

$40

Median target, all firms

$57

Actions on MRNA

3

Wolfe Research price target on MRNA

Every Wolfe Research rating on MRNA

• Aug 25, 2026
  UpgradeWolfe Research upgrades to Peer Perform from Underperform
• Nov 15, 2024
  InitiateWolfe Research starts coverage at Underperform, price target $40
• Nov 9, 2021
  InitiateWolfe Research starts coverage at Outperform, price target $304

How other firms rate MRNA

Each firm's latest rating and stated target in the last 12 months.

Questions about Wolfe Research and MRNA

What is Wolfe Research's price target for MRNA?

Wolfe Research's latest stated price target for Moderna Inc. (MRNA) is $40, from its action on Nov 15, 2024.

What is Wolfe Research's rating on MRNA?

Wolfe Research rates MRNA Peer Perform, a neutral rating, as of Aug 25, 2026.

When did Wolfe Research last change its view on MRNA?

On Aug 25, 2026, Wolfe Research upgrades to Peer Perform from Underperform.

How does Wolfe Research's MRNA target compare with other analysts?

Across 6 firms with a MRNA price target in the last 12 months, the median target is $57.

More MRNA rating histories

• William Blair3
• Argus Research3
• BofA Securities3
• Barclays4
• UBS3
• Jefferies5
• HSBC5
• Oppenheimer3
• Deutsche Bank7
• TD Cowen4
• Leerink Partners5
• Morgan Stanley5
• Piper Sandler3

All Wolfe Research ratingsMRNA news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.